Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug ...
Barchart on MSN2d
What to Expect From Catalent's Next Quarterly Earnings ReportCatalent, Inc. (CTLT), headquartered in Somerset, New Jersey, is a significant provider in the pharmaceutical and biotech ...
The advocacy groups said at the time that the deal could constrain competitors such as Amgen, Pfizer, Roche and AstraZeneca, ...
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...
On Tuesday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.92 which represents a decrease of $-0.26 or -0.43% from the prior close of $60.18. The stock opened at $60.14 and touched a ...
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...
Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...
Yale spinout Modifi agreed to sell to Merck for $30 million upfront. Elsewhere, Sangamo plotted a much faster path to market ...
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...
Roche CEO Urges FTC to Block Novo Nordisks Acquisition of Catalent Roches CEO, Thomas Schinecker, has called on authorities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback